Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Esteve Pharmaceuticals discloses new analgesics

Feb. 12, 2020

Prolactin could explain sex differences in pain syndromes

Feb. 12, 2020

Novartis studies BLZ-945 in phase II trial for ALS

Feb. 12, 2020

Phase III trial of troriluzole in generalized anxiety disorder misses primary endpoint

Feb. 11, 2020

Discovery of macrocyclic ASK1 inhibitors with potential applications in neurodegenerative diseases

Feb. 11, 2020

Lilly reports topline results on solanezumab from DIAN-TU study

Feb. 10, 2020

Gantenerumab arm of DIAN-TU study did not meet primary endpoint

Feb. 10, 2020

Myelin is deregulated in autism spectrum disorder

Feb. 10, 2020

Boehringer Ingelheim patents GABA(A) receptor subunits alpha5beta3gamma2 negative modulators

Feb. 10, 2020

Sumitomo Dainippon Pharma describes new Nav1.1 channel activators

Feb. 10, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...